Stem cell therapy for dilated cardiomyopathy

CONCLUSIONS: We are uncertain whether SCT in people with DCM reduces the risk of all-cause mortality and procedural complications, improves HRQoL, and performance status (exercise capacity). SCT may improve functional class (NYHA), compared to usual care (no cells). Similarly, when compared to G-CSF, we are also uncertain whether SCT in people with DCM reduces the risk of all-cause mortality although some studies within this comparison observed a favourable effect that should be interpreted with caution. SCT may not improve HRQoL but may improve to some extent performance status (exercise capacity). Very low-quality evidence reflects uncertainty regarding procedural complications. These suggested beneficial effects of SCT, although uncertain due to the very low certainty of the evidence, are accompanied by favourable effects on some physiological measures of cardiac function. Presently, the most effective mode of administration of SCT and the population that could benefit the most is unclear. Therefore, it seems reasonable that use of SCT in people with DCM is limited to clinical research settings. Results of ongoing studies are likely to modify these conclusions.PMID:34286511 | DOI:10.1002/14651858.CD013433.pub2

Source: Cochrane Database of Systematic Reviews - July 21, 2021 Category: General Medicine Authors: Rienzi Diaz-Navarro Gerard Urr útia John Gf Cleland Daniel Poloni Francisco Villagran Roberto Acosta-Dighero Shrikant I Bangdiwala Gabriel Rada Eva Madrid Source Type: research